Skip to main content

Teniposide Dosage

Applies to the following strengths: 10 mg/mL

Usual Adult Dose for Acute Lymphoblastic Leukemia

Patients failing induction therapy with a cytarabine-containing regimen:
165 mg/m2 IV over at least 30 to 60 minutes and 300 mg/m2 cytarabine IV twice weekly for 8 to 9 doses

Patients refractory to vincristine/prednisone-containing regimens:
250 mg/m2 IV over at least 30 to 60 minutes and 1.5 mg/m2 vincristine IV weekly for 4 to 8 weeks with 40 mg/m2 prednisone orally for 28 days

Use: For induction therapy in patients with refractory childhood acute lymphoblastic leukemia (ALL) in combination with other approved anticancer agents

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

Patients failing induction therapy with a cytarabine-containing regimen:
14 days and older:
165 mg/m2 IV over at least 30 to 60 minutes and 300 mg/m2 cytarabine IV twice weekly for 8 to 9 doses

Patients refractory to vincristine/prednisone-containing regimens:
14 days and older:
250 mg/m2 IV over at least 30 to 60 minutes and 1.5 mg/m2 vincristine IV weekly for 4 to 8 weeks with 40 mg/m2 prednisone orally for 28 days

Use: For induction therapy in patients with refractory childhood acute lymphoblastic leukemia (ALL) in combination with other approved anticancer agents

Renal Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Liver Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Dose Adjustments

Patients with both Down syndrome and leukemia may be especially sensitive to myelosuppressive chemotherapy; therefore, initial dosing should be reduced in these patients. It is suggested that the first course should be given at half the usual dose. Subsequent courses may be administered at higher doses depending on the degree of myelosuppression and mucositis encountered in earlier courses.

Precautions

US BOXED WARNINGS:

used to alleviate symptoms.

CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 14 days.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

General:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.